Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity

BORIS DOI
Publisher DOI
PubMed ID
36087505
Date of Publication
2022
Publication Type
Article
Subject(s)
600 - Technology::610 - Medicine & health
500 - Science::570 - Life sciences; biology
Language(s)
en
Contributor(s)
Nowak, Albina
Dormond, Olivier
Monzambani, Véronique
Barbey, Frédéric
Additional Credits
Universitätsklinik für Nephrologie und Hypertonie
Series
Molecular genetics and metabolism
Publisher
Elsevier
ISSN
1096-7192
Access(Rights)
open.access
Show full item